Literature DB >> 31176270

Ovarian cancer relapse: From the latest scientific evidence to the best practice.

Daniela Luvero1, Francesco Plotti2, Alessia Aloisia2, Roberto Montera2, Corrado Terranova2, Giuseppe Scaletta3, Salvatore Lopez2, Andrea Miranda2, Stella Capriglione2, Alessandra Gatti2, Roberto Angioli2.   

Abstract

Ovarian cancer (OC) is the fifth most common cause of cancer death in women worldwide. Despite treatment options have continued to improve in recent years, the recurrence rate is still high; in fact around 80% of patients relapses within 18 months. Recently, the scientific landscape is agree in asserting that the ovarian cancer is not a single disease but the outcome of patients depends from the molecular and biological characterization of tumor tissue. In this scenario, molecular targeted therapy given alone or in combination with chemotherapy is showing significant results. We review the different options for the treatment of ovarian cancer recurrence, including the role of surgery, in order to try outlining a possible treatment algorithm evaluating the recent scientific literature and the most important trials.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Ovarian cancer; Parp inhibitors; Recurrence

Mesh:

Substances:

Year:  2019        PMID: 31176270     DOI: 10.1016/j.critrevonc.2019.05.014

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  14 in total

1.  Cardamonin inhibits the expression of P-glycoprotein and enhances the anti-proliferation of paclitaxel on SKOV3-Taxol cells.

Authors:  Qiuhua Ding; Peiguang Niu; Yanting Zhu; Huajiao Chen; Daohua Shi
Journal:  J Nat Med       Date:  2021-11-09       Impact factor: 2.343

2.  Initiation and elongation factor co-expression correlates with recurrence and survival in epithelial ovarian cancer.

Authors:  Monika Sobočan; Daniela Brunialti; Sussanne Sprung; Christoph Schatz; Jure Knez; Rajko Kavalar; Iztok Takač; Johannes Haybaeck
Journal:  J Ovarian Res       Date:  2022-06-19       Impact factor: 5.506

3.  HIF-1α Regulated WTAP Overexpression Promoting the Warburg Effect of Ovarian Cancer by m6A-Dependent Manner.

Authors:  Yuanyuan Lyu; Yilin Zhang; Yuhan Wang; Yonghong Luo; Huafeng Ding; Peiling Li; Guantai Ni
Journal:  J Immunol Res       Date:  2022-06-12       Impact factor: 4.493

4.  SLC7A2 serves as a potential biomarker and therapeutic target for ovarian cancer.

Authors:  Tianshui Sun; Fangfang Bi; Zhuonan Liu; Qing Yang
Journal:  Aging (Albany NY)       Date:  2020-07-09       Impact factor: 5.682

5.  Lidocaine inhibits the metastatic potential of ovarian cancer by blocking NaV 1.5-mediated EMT and FAK/Paxillin signaling pathway.

Authors:  Chang Liu; Ming Yu; Yi Li; Hao Wang; Chuanya Xu; Xiaoqing Zhang; Min Li; Hongyan Guo; Daqing Ma; Xiangyang Guo
Journal:  Cancer Med       Date:  2020-12-06       Impact factor: 4.452

6.  Knockdown of growth factor receptor bound protein 7 suppresses angiogenesis by inhibiting the secretion of vascular endothelial growth factor A in ovarian cancer cells.

Authors:  Qiong Xu; Zequn Liu; Zhi-Qin Zhu; Yue Fan; Rui Chen; Xiao-Hui Xie; Mi Cheng
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

7.  Circular RNA lysophosphatidic acid receptor 3 (circ-LPAR3) enhances the cisplatin resistance of ovarian cancer.

Authors:  Xuemei Liu; Zhiping Yin; Yanjun Wu; Qian Zhan; Honghong Huang; Jiangtao Fan
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

Review 8.  The rediscovery of platinum-based cancer therapy.

Authors:  Sven Rottenberg; Carmen Disler; Paola Perego
Journal:  Nat Rev Cancer       Date:  2020-10-30       Impact factor: 60.716

9.  The survival outcome and complication of secondary cytoreductive surgery plus chemotherapy in recurrent ovarian cancer: a systematic review and meta-analysis.

Authors:  Ting Ding; Dan Tang; Mingrong Xi
Journal:  J Ovarian Res       Date:  2021-07-13       Impact factor: 4.234

10.  Garcinol Alone and in Combination With Cisplatin Affect Cellular Behavior and PI3K/AKT Protein Phosphorylation in Human Ovarian Cancer Cells.

Authors:  Jie Zhang; Huan Fang; Jinguo Zhang; Wencai Guan; Guoxiong Xu
Journal:  Dose Response       Date:  2020-05-19       Impact factor: 2.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.